Meeting
2016 ASCO Annual Meeting
A multicenter, randomized, double-blind, placebo-controlled phase III study of monosialoganglioside (GM1) preventing neurotoxicity induced by cisplatin-based chemotherapy in non-small cell lung cancer patients.
Authors
Li Zhang
Sun Yat-sen University Cancer Center, Guangzhou, China
Li Zhang , Ting Zhou , Yuxiang Ma , Yunpeng Yang , Wenfeng Fang , Yuangyuan Zhao , Shaodong Hong , Chan Fang , Jiexia Zhang , Hongyu Zhang , Hongyun Zhao , Yan Huang
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Patient and Survivor Care
Track
Patient and Survivor Care
Sub Track
Palliative Care and Symptom Management
Clinical Trial Registration Number
NCT01882621
Citation
J Clin Oncol 34, 2016 (suppl; abstr TPS10142)
DOI
10.1200/JCO.2016.34.15_suppl.TPS10142
Abstract #
TPS10142
Poster Bd #
129a
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
A randomized, double-blind, phase 3 trial of MK-7684A plus chemotherapy versus pembrolizumab plus chemotherapy as first-line therapy for metastatic non–small cell lung cancer (NSCLC): KeyVibe-007.
First Author: Marina Chiara Garassino
Poster
2019 ASCO Annual Meeting
CANOPY-A: A phase III study of canakinumab as adjuvant therapy in patients with surgically resected non-small cell lung cancer (NSCLC).
First Author: Edward B. Garon
Poster
2018 ASCO Annual Meeting
Randomized, double-blind, phase III trial of monosialotetrahexosylganglioside versus placebo in GI cancer patients with oxaliplatin induced peripheral neurotoxicity (TJMUCH-GI-001).
First Author: Zhou Likun
Poster
2018 ASCO Annual Meeting
Randomized, double-blind phase 3 study evaluating neoadjuvant platinum-based chemotherapy with perioperative pembrolizumab or placebo in resectable stage IIB or IIIA NSCLC: KEYNOTE-671.
First Author: Hiran C. Fernando